Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mesothelioma Stratified Therapy (MiST): A Stratified Multi-arm Phase IIa Clinical Trial to Enable Accelerated Evaluation of Targeted Therapies for Relapsed Malignant Mesothelioma

Trial Profile

Mesothelioma Stratified Therapy (MiST): A Stratified Multi-arm Phase IIa Clinical Trial to Enable Accelerated Evaluation of Targeted Therapies for Relapsed Malignant Mesothelioma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Feb 2019

At a glance

  • Drugs Abemaciclib (Primary) ; Atezolizumab (Primary) ; Bemcentinib (Primary) ; Bevacizumab (Primary) ; Pembrolizumab (Primary) ; Rucaparib (Primary)
  • Indications Mesothelioma
  • Focus Therapeutic Use
  • Acronyms MiST
  • Most Recent Events

    • 01 Oct 2018 Status changed from not yet recruiting to recruiting.
    • 26 Sep 2018 According to the trial design presented at the 19th World Conference on Lung Cancer, first patient first visit is anticipated in Q3 2018.
    • 26 Sep 2018 Trial design of MIST3 presented at the 19th World Conference on Lung Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top